secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIPELLA PHARMACEUTICALS INC. (LIPO)
CIK:        0001347242
Form:       8-K
Filed at:   2023-01-12T23:59:59+00:00
Accession:  0001753926-23-000046
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipella reports positive Phase 2a results for LP-10 in hemorrhagic cystitis
---------------------------------------------------------------------------

- All 13 subjects tolerated LP-10 without product-related serious adverse events.
- Dose response observed: decreased hematuria, cystoscopic bleeding/ulceration, improved urinary symptoms.
- Responder analysis: complete response in 3 subjects, partial in 7, no response in 3 subjects.
- LP-10 has Orphan Drug Designation; no FDA-approved treatment exists for hemorrhagic cystitis.
- CEO to present results at Biotech Showcase 2023 on January 11, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347242/000175392623000046/0001753926-23-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347242/000175392623000046/g083352_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-23-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer